Jun 04, 2023 / 11:00PM GMT
Jeremy Bender - CEO - Day One Biopharmaceuticals Inc.
-- at ASCO 2023 with our team from day one and with so many of our important partners. Partners who've joined us on our mission to bring treatment options to children and adults suffering from the effects of cancer and other life-threatening diseases. Our data from FIREFLY-1, which is our pivotal study in relapsed or progressive pediatric low-grade glioma, were shared this morning in an oral session by Dr. Lindsay Kilburn of Children's National Hospital.
In addition to reviewing these data, we'll provide additional updates on this call about day one, focusing on the regulatory and clinical impact of FIREFLY-1. As we provide this important update, it's critical to keep in mind that day one was created to address the innovation gap between pediatric and adult patients living with cancer and other life-threatening diseases.
That gap is approximately six years. That's how much longer, on average, children have to wait than adults for access to life-saving cancer treatments. At day one, we aim to re-envision cancer drug development and
Day One Biopharmaceuticals Inc Conference Call Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers